Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
Cancer genome sequencing is the whole genome sequencing of a single, homogeneous or heterogeneous group of cancer cells.
OMICS International organizes 22 Conferences/Workshops on Cancer Cell Biology, 12 Symposium with 13 Speakers till date.
OMICS International Organizes 300+ conferences, 500+workshops and 200+symposiums on Clinical, Medicine, Pharma, Science & Technology every year across USA, Europe, Asia, Middle East, Australia and UK with support from 1000 more Scientific Societies and Publishes 500 open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members. The OMICS International Conferences are instrumental in giving a serious stage to the incredibly famous scientists, understudies, researchers, academicians, organizations, business visionaries and businesses through its 300+ International Conferences and occasions yearly all through the globe to raise and examine the advancements in the field of OMICS Study. OMICS International Conferences are completely pressed with intriguing occasions, exercises and learning going with the quick entrepreneurial enthusiasm to make them genuine. They are multidimensional with synchronous movement situated symposia, International workshops and presentations where the identities from Sciences (Both unadulterated & connected), Pharmaceutical, Medical, Clinical, Engineering & Technology and Life Sciences accumulate with their procedures in discovering genuine answers for different basic issues around the globe.
Scope & Importance
Mutational analysis of entire gene families has been a powerful approach to oncogenomics which has been informative. Genes of the same family have similar functions, as predicted by similar coding sequences and protein domains, have been systematically sequenced in cancerous genomes to identify particular pathways which may be associated with cancer progression
Cancer Genomics is concerned with:
· Mutations in mitochondrial DNA and cancerTherapy (e.g. surgery, chemotherapy, radiotherapy and other modalities)
· Quantitative mtDNA alterations (copy number mutations)Palliative care of patients with terminal malignancies
· Ethical questions surrounding cancer care
Anticancer drugs have been manufactured to target mtDNA and have shown positive results in killing tumor cells. There has also been research done in using mitochondrial mutations as biomarkers for cancer cell therapy. It is easier to target mutation within the mitochondrial DNA as opposed to nuclear DNA because the mitochondrial genome is much smaller and therefore easier to screen for specific mutations. It is also thought that the mtDNA content alterations found in blood samples might be able to serve as a screening marker for predicting future cancer susceptibility as well as tracking malignant tumor progression. Along with these potential helpful characteristics of mtDNA, it is also not under the control of the cell cycle and it is important for maintaining ATP generation and mitochondrial homeostasis. These characteristics make targeting mtDNA a practical therapeutic strategy
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia).
The global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020. The biological therapies are expected to dominate the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.
Geographically, North America, dominates the market followed by Europe. North America accounted for about ~38% share in the overall oncology drugs market in 2013 owing to the heavy investments by multinational companies in research and development of cancer drugs. On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period.
List of International Conferences on Oncology
List of major Associations and Societies on Oncology
List of Key Companies
This page will be updated regularly.
This page was last updated on February 24, 2021